9.23
+0.1982(+2.19%)
Currency In USD
| Previous Close | 9.03 |
| Open | 9.1 |
| Day High | 9.37 |
| Day Low | 8.78 |
| 52-Week High | 11.68 |
| 52-Week Low | 2.11 |
| Volume | 2.63M |
| Average Volume | 4.9M |
| Market Cap | 848.19M |
| PE | -6.59 |
| EPS | -1.4 |
| Moving Average 50 Days | 8.69 |
| Moving Average 200 Days | 6.48 |
| Change | 0.2 |
If you invested $1000 in ASP Isotopes Inc. Common Stock (ASPI) since IPO date, it would be worth $3,456.25 as of August 22, 2025 at a share price of $9.228. Whereas If you bought $1000 worth of ASP Isotopes Inc. Common Stock (ASPI) shares 2 years ago, it would be worth $7,626.61 as of August 22, 2025 at a share price of $9.228.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ASP Isotopes Inc. and its Subsidiary, Quantum Leap Energy LLC, enter into a Memorandum of Understanding with Fermi America Regarding a Joint Venture to Collaborate on the Research, Development and Construction of an Advanced Nuclear Fuel Research and Production Facility at the Planned 11GW HyperGrid Campus in Carson County, Texas
GlobeNewswire Inc.
Aug 15, 2025 12:55 PM GMT
- Fermi America is a private U.S. developer of the planned HyperGrid campus near Amarillo, Texas, which is leased from Texas Tech University and is expected to be the world’s largest hybrid energy and data infrastructure campus providing 11GW of powe
ASP Isotopes Inc. Announces Expected Commencement of Dual Listing on Johannesburg Stock Exchange
GlobeNewswire Inc.
Aug 08, 2025 1:00 PM GMT
WASHINGTON, Aug. 08, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), an advanced materials company dedicated to the development of technology and processes for the production of isotopes for use in multipl
ASP Isotopes Inc. and IsoBio, Inc. Announce Series Seed Funding of IsoBio, Inc. to Advance Innovative Antibody-Isotope Conjugates (AICsTM) For Cancer Treatment
GlobeNewswire Inc.
Jul 28, 2025 12:31 PM GMT
- IsoBio, Inc. (IsoBio) is a U.S.-based radiotherapeutic development company focused on developing a broad pipeline of mAb-based radioisotope therapeutics, known as antibody-isotope conjugates (AICsTM), targeting both derisked and novel tumor antigen